# Efficacy and Safety of NicVAX® Co-administered With Varenicline (Champix®)

> **NCT00995033** · PHASE2 · COMPLETED · sponsor: **Maastricht University Medical Center** · enrollment: 558 (actual)

## Conditions studied

- Smoking Behavior
- Smoking Lapse Behavior
- Smoking Relapse Behavior

## Interventions

- **BIOLOGICAL:** NicVAX vaccine
- **BIOLOGICAL:** Placebo
- **DRUG:** Varenicline

## Key facts

- **NCT ID:** NCT00995033
- **Lead sponsor:** Maastricht University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 558 (ACTUAL)
- **Last updated:** 2013-02-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00995033

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00995033, "Efficacy and Safety of NicVAX® Co-administered With Varenicline (Champix®)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00995033. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*